Tennessee’s innovative clinical trials network is soaring just one year into operations, bringing growing benefits for Tennesseans and the advancement of health care across the state. Launched in April 2018, the Clinical Trials Network of Tennessee (CTN2) has already...
Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis and Haemostasis Company to host investor call and webcast on Monday,...
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human...
Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and...
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate...
300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President,...
Email
Text